Captor Therapeutics Spolka Akcyjna (WSE:CTX)
Poland · Delayed Price · Currency is PLN 64.00
-1.50 (-2.29%)
Oct 9, 2026, 4:59 PM CET
WSE:CTX Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.01 | 4.66 | 15.83 | 13.2 | 9.16 | 3.99 | |
Revenue Growth | -81.93% | -70.55% | 19.88% | 44.15% | 129.75% | - |
Cost of Revenue | -1.85 | 1.45 | 5.23 | 6.3 | 2.09 | 0.74 |
Gross Profit | 3.85 | 3.22 | 10.6 | 6.9 | 7.07 | 3.25 |
Selling, General & Admin | 8.07 | 11.14 | 11.46 | 16.14 | 24.07 | 30.68 |
Research & Development | 48.9 | 45.29 | 43.9 | 70.89 | 44.16 | 23.12 |
Other Operating Expenses | -6.75 | -9.57 | -5.79 | -7.11 | -22.79 | -17.71 |
Operating Expenses | 50.22 | 46.85 | 49.56 | 79.92 | 45.44 | 36.09 |
Operating Income | -46.36 | -43.63 | -38.97 | -73.02 | -38.36 | -32.84 |
Interest Expense | -0.26 | -0.28 | -0.39 | -0.27 | -0.32 | -0.4 |
Interest & Investment Income | 2.36 | 1.82 | 1.04 | 3.08 | 3.13 | - |
Currency Exchange Gain (Loss) | -0.07 | 0.03 | -0.07 | -0.27 | -0.08 | -0.06 |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.05 | -0.05 | -0.26 | -0.41 |
EBT Excluding Unusual Items | -44.33 | -42.07 | -38.43 | -70.53 | -35.89 | -33.7 |
Gain (Loss) on Sale of Assets | 0.07 | 0.07 | - | - | - | - |
Asset Writedown | - | - | - | - | - | 1.13 |
Pretax Income | -44.26 | -42 | -38.43 | -70.53 | -35.89 | -32.57 |
Income Tax Expense | 0.03 | - | - | 0.06 | - | - |
Net Income | -44.29 | -42 | -38.43 | -70.58 | -35.89 | -32.57 |
Net Income to Common | -44.29 | -42 | -38.43 | -70.58 | -35.89 | -32.57 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 6 | 6 | 5 | 5 | 4 | 4 |
Shares Outstanding (Diluted) | 6 | 6 | 5 | 5 | 4 | 4 |
Shares Change | 12.34% | 18.42% | 0.30% | 11.46% | 0.97% | 14.99% |
EPS (Basic) | -7.76 | -7.61 | -8.25 | -15.19 | -8.61 | -7.89 |
EPS (Diluted) | -7.76 | -7.61 | -8.25 | -15.19 | -8.61 | -7.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -74.78 | -37.53 | -32.3 | -55.21 | -23.84 | -33.59 |
Free Cash Flow Per Share | -13.10 | -6.80 | -6.93 | -11.88 | -5.72 | -8.14 |
Gross Margin | 192.12% | 68.99% | 66.95% | 52.28% | 77.21% | 81.41% |
Operating Margin | -2311.12% | -936.33% | -246.24% | -553.11% | -418.91% | -823.88% |
Profit Margin | -2207.63% | -901.22% | -242.82% | -534.69% | -391.94% | -817.16% |
Free Cash Flow Margin | -3727.57% | -805.36% | -204.12% | -418.22% | -260.32% | -842.60% |
EBITDA | -42.75 | -39.27 | -33.91 | -67.58 | -31.27 | -25.49 |
EBITDA Margin | - | - | -214.27% | - | - | - |
D&A For EBITDA | 3.61 | 4.37 | 5.06 | 5.44 | 7.09 | 7.36 |
EBIT | -46.36 | -43.63 | -38.97 | -73.02 | -38.36 | -32.84 |
EBIT Margin | - | - | -246.24% | - | - | - |